Search

Your search keyword '"Wen, Xiaona"' showing total 23 results
Start Over Author "Wen, Xiaona"
23 results on '"Wen, Xiaona"'

4. Diagnosis of pregnancy disorder in the first‐trimester patient plasma with Raman spectroscopy and protein analysis.

Author

Mathew, Ansuja P., Cutshaw, Gabriel, Appel, Olivia, Funk, Meghan, Synan, Lilly, Waite, Joshua, Ghazvini, Saman, Wen, Xiaona, Sarkar, Soumik, Santillan, Mark, Santillan, Donna, and Bardhan, Rizia

Subjects
GESTATIONAL diabetes, RAMAN spectroscopy, PLASMA spectroscopy, MEDICAL screening, BLOOD sugar, PLACENTAL growth factor
Abstract

Gestational diabetes mellitus (GDM) is a pregnancy disorder associated with short‐ and long‐term adverse outcomes in both mothers and infants. The current clinical test of blood glucose levels late in the second trimester is inadequate for early detection of GDM. Here we show the utility of Raman spectroscopy (RS) for rapid and highly sensitive maternal metabolome screening for GDM in the first trimester. Key metabolites, including phospholipids, carbohydrates, and major amino acids, were identified with RS and validated with mass spectrometry, enabling insights into associated metabolic pathway enrichment. Using classical machine learning (ML) approaches, we showed the performance of the RS metabolic model (cross‐validation AUC 0.97) surpassed that achieved with patients' clinical data alone (cross‐validation AUC 0.59) or prior studies with single biomarkers. Further, we analyzed novel proteins and identified fetuin‐A as a promising candidate for early GDM prediction. A correlation analysis showed a moderate to strong correlation between multiple metabolites and proteins, suggesting a combined protein‐metabolic analysis integrated with ML would enable a powerful screening platform for first trimester diagnosis. Our study underscores RS metabolic profiling as a cost‐effective tool that can be integrated into the current clinical workflow for accurate risk stratification of GDM and to improve both maternal and neonatal outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Metabolic Response to Small Molecule Therapy in Colorectal Cancer Tracked with Raman Spectroscopy and Metabolomics.

Author

Cutshaw, Gabriel, Joshi, Neeraj, Wen, Xiaona, Quam, Elizabeth, Bogatcheva, Galina, Hassan, Nora, Uthaman, Saji, Waite, Joshua, Sarkar, Soumik, Singh, Bhuminder, and Bardhan, Rizia

Subjects
MACHINE learning, PRIMARY cell culture, SUPERVISED learning, METABOLIC reprogramming, RAMAN spectroscopy, CETUXIMAB
Abstract

Despite numerous screening tools for colorectal cancer (CRC), 25 % of patients are diagnosed with advanced disease. Novel diagnostic technologies that are early, accurate, and rapid are imperative to assess the therapeutic efficacy of clinical drugs and identify new biomarkers of treatment response. Here Raman spectroscopy (RS) was used to track metabolic reprogramming in KRAS‐mutant HCT116 and SW837 cells, and KRAS wild‐type CC cells. RS combined with multivariate analysis methods distinguished nonresponsive, partially responsive, and responsive cells treated with cetuximab, a monoclonal antibody for EGFR inhibition, sotorasib, a clinically approved KRAS inhibitor, and various doses of trametinib, an inhibitor of the MAPK pathway. Cells treated with a combination of subtoxic doses of trametinib and BKM120, an inhibitor of the PI3K pathway, showed a synergistic response between the two pathways. Using a supervised machine learning regression model, we established a scoring methodology trained to a priori predict therapeutic response to new treatment combinations. RS metabolites were verified with mass spectrometry, and enrichment pathways were identified, including amino acid, purine, and nicotinate and nicotinamide metabolism that differentiated monotherapy from combination therapy. Our approach may ultimately be applicable to patient‐derived primary cells and cultures of patient tumors to predict effective drugs for individualized care. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy

Author

Wang-Bishop, Lihong, primary, Kimmel, Blaise R., additional, Ngwa, Verra M., additional, Madden, Matthew Z., additional, Baljon, Jessalyn J., additional, Florian, David C., additional, Hanna, Ann, additional, Pastora, Lucinda E., additional, Sheehy, Taylor L., additional, Kwiatkowski, Alexander J., additional, Wehbe, Mohamed, additional, Wen, Xiaona, additional, Becker, Kyle W., additional, Garland, Kyle M., additional, Schulman, Jacob A., additional, Shae, Daniel, additional, Edwards, Deanna, additional, Wolf, Melissa M., additional, Delapp, Rossane, additional, Christov, Plamen P., additional, Beckermann, Kathryn E., additional, Balko, Justin M., additional, Rathmell, W. Kimryn, additional, Rathmell, Jeffrey C., additional, Chen, Jin, additional, and Wilson, John T., additional

Published
2023
Full Text
View/download PDF

12. Mammary Tissue-Derived Extracellular Matrix Hydrogels Reveal the Role of the Irradiated Microenvironment in Breast Cancer Recurrence

Author

Zhu, Tian, primary, Alves, Steven M., additional, Adamo, Arianna, additional, Wen, Xiaona, additional, Corn, Kevin C., additional, Shostak, Anastasia, additional, Shaub, Nicholas D., additional, Hacker, Benjamin C., additional, D’Amore, Antonio, additional, Bardhan, Rizia, additional, and Rafat, Marjan, additional

Published
2022
Full Text
View/download PDF

16. The tumor phototherapeutic application of nanoparticles constructed by the relationship between PTT/PDT efficiency and 2,6- and 3,5-substituted BODIPY derivatives

Author

Yin, Juanjuan, primary, Jiang, Xu, additional, Sui, Guomin, additional, Du, Yingying, additional, Xing, Enyun, additional, Shi, Ruijie, additional, Gu, Chengzhi, additional, Wen, Xiaona, additional, Feng, Yaqing, additional, Shan, Zhongqiang, additional, and Meng, Shuxian, additional

Published
2021
Full Text
View/download PDF

17. Correction to “Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies”

Author

Ou, Yu-Chuan, primary, Wen, Xiaona, additional, Johnson, Christopher A., additional, Shae, Daniel, additional, Ayala, Oscar D., additional, Webb, Joseph A., additional, Lin, Eugene C., additional, DeLapp, Rossane C., additional, Boyd, Kelli L., additional, Richmond, Ann, additional, Mahadevan-Jansen, Anita, additional, Rafat, Marjan, additional, Wilson, John T., additional, Balko, Justin M., additional, Tantawy, Mohammed N., additional, Vilgelm, Anna E., additional, and Bardhan, Rizia, additional

Published
2020
Full Text
View/download PDF

18. PRADA: Portable Reusable Accurate Diagnostics with nanostar Antennas for multiplexed biomarker screening

Author

Wen, Xiaona, primary, Ou, Yu‐Chuan, additional, Zarick, Holly F., additional, Zhang, Xin, additional, Hmelo, Anthony B., additional, Victor, Quinton J., additional, Paul, Eden P., additional, Slocik, Joseph M., additional, Naik, Rajesh R., additional, Bellan, Leon M., additional, Lin, Eugene C., additional, and Bardhan, Rizia, additional

Published
2020
Full Text
View/download PDF

20. Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies

Author

Ou, Yu-Chuan, primary, Wen, Xiaona, additional, Johnson, Christopher A., additional, Shae, Daniel, additional, Ayala, Oscar D., additional, Webb, Joseph A., additional, Lin, Eugene C., additional, DeLapp, Rossane C., additional, Boyd, Kelli L., additional, Richmond, Ann, additional, Mahadevan-Jansen, Anita, additional, Rafat, Marjan, additional, Wilson, John T., additional, Balko, Justin M., additional, Tantawy, Mohammed N., additional, Vilgelm, Anna E., additional, and Bardhan, Rizia, additional

Published
2019
Full Text
View/download PDF

21. Multiproduct Resin Reuse for Clinical and Commercial Manufacturing—Methodology and Acceptance Criteria

Author

Sharnez, Rizwan, primary, Doares, Steve, additional, Manning, Shane, additional, Mehta, Krunal, additional, Mahajan, Ekta, additional, To, Angela, additional, Daniels, William, additional, Glynn, Judy, additional, Dhamane, Sagar, additional, Wen, Xiaona, additional, Wang, Yunjuan, additional, Gour, Pankaj, additional, Guenther, Constanze, additional, Foley, Derek, additional, Hayes, Ronan, additional, Mott, Adam, additional, Prabhu, Sunil, additional, Tavalsky, Dawn, additional, Hendershot, Michael, additional, Haas, David, additional, Hesslein, Ashley, additional, Schuelke, Norbert, additional, and Tjandra, Hendri, additional

Published
2018
Full Text
View/download PDF

22. Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies

Author

Ou, Yu-Chuan, Wen, Xiaona, Johnson, Christopher A., Shae, Daniel, Ayala, Oscar D., Webb, Joseph A., Lin, Eugene C., DeLapp, Rossane C., Boyd, Kelli L., Richmond, Ann, Mahadevan-Jansen, Anita, Rafat, Marjan, Wilson, John T., Balko, Justin M., Tantawy, Mohammed N., Vilgelm, Anna E., and Bardhan, Rizia

Abstract

The overexpression of immunomarker programmed cell death protein 1 (PD-1) and engagement of PD-1 to its ligand, PD-L1, are involved in the functional impairment of cluster of differentiation 8+(CD8+) T cells, contributing to cancer progression. However, heterogeneities in PD-L1 expression and variabilities in biopsy-based assays render current approaches inaccurate in predicting PD-L1 status. Therefore, PD-L1 screening alone is not predictive of patient response to treatment, which motivates us to simultaneously detect multiple immunomarkers engaged in immune modulation. Here, we have developed multimodal probes, immunoactive gold nanostars (IGNs), that accurately detect PD-L1+tumor cells and CD8+T cells simultaneously in vivo, surpassing the limitations of current immunoimaging techniques. IGNs integrate the whole-body imaging of positron emission tomography with high sensitivity and multiplexing of Raman spectroscopy, enabling the dynamic tracking of both immunomarkers. IGNs also monitor response to immunotherapies in mice treated with combinatorial PD-L1 and CD137 agonists and distinguish responders from those nonresponsive to treatment. Our results showed a multifunctional nanoscale probe with capabilities that cannot be achieved with either modality alone, allowing multiplexed immunologic tumor profiling critical for predicting early response to immunotherapies.

Published
2020
Full Text
View/download PDF

23. [Study on the modification surface material of heparinized polyurethane].

Author

Meng S, Wen X, Feng Y, and Gu H

Subjects
Blood Coagulation Tests, Humans, Materials Testing, Partial Thromboplastin Time, Polyurethanes chemical synthesis, Surface Properties, Coated Materials, Biocompatible chemistry, Heparin pharmacology, Polyurethanes chemistry
Abstract

In this study cationic and heparinized polyurethanes (PUs) were synthesized by a two-step solution polymerized method. Cationic and heparinized PUs were investigated by infrared spectroscopy, electron spectroscopy for chemical analysis (ESCA) and turbidity method. At the same time, the PUs proved of good biocompatibility through the laboratory tests, including blood coagulation time (CT), activated partial thromb plastin time (APTT) and fibroblast culture. These materials have good biocompatible function.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results